The Lancet Psychiatry (04/06/21) DOI: 10.1016/S2215-0366(21)00084-5
Taquet, Maxime; Geddes, John R.; Husain, Masud; et al.
Approximately a third of people diagnosed with COVID-19 exhibited longer term neurological and psychiatric symptoms, a new study shows. For the retrospective cohort study, researchers from the University of Oxford examined the health records of 236,379 patients in the six months following their COVID-19 diagnosis and estimated the incidence of 14 neurological and psychiatric outcomes during that time. The estimated incidence of any neurological or psychiatric diagnosis within six months of diagnosis was 33.62% — and for 12.84% of them, the diagnosis was new. The most common diagnoses were anxiety (17.39%), mood disorders (13.66%), and substance use disorder (6.58%). For those admitted to an intensive care unit, the estimated incidence of a neurological or psychiatric diagnosis was 46.62%, including 25.79% for whom the diagnosis was new. Common diagnoses in this group included anxiety (19.15%), mood disorder (15.43%), substance use disorder (10.14%), and ischemic stroke (6.92%). "Overall, COVID-19 was associated with increased risk of neurological and psychiatric outcomes, but the incidences and HRs of these were greater in patients who had required hospitalization, and markedly so in those who had required ITU admission or had developed encephalopathy, even after extensive propensity score matching for other factors (e.g., age or previous cerebrovascular disease)," the researchers report.